SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for BIOLARGO, INC. (BLGO) (CIK 0000880242) (BLGO) — Feb 8, 2018

BIOLARGO, INC. (BLGO) (CIK 0000880242)
Date: Feb. 8, 2018 · CIK: 0000880242 · Accession: 0000000000-18-004410

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-222572

Date
February 8, 2018
Author
/s/ Jay Ingram
Form
UPLOAD
Company
BIOLARGO, INC. (BLGO) (CIK 0000880242)

Letter

February 8, 2018 Dennis P. Calvert Chief Executive Officer, BioLargo, Inc. 14921 Chestnut St. Westminster, CA 92683

Re: BioLargo, Inc . Amendment No. 1 to Registration Statement on Form S-1 Filed February 7 , 2018 File No. 333-222572

Dear Mr. Calvert:

We have limited our review of your registration statement to those issues we have addressed in our comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to this letter by amending your registration statement and providing the requested information . If you do not believe our com ments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you provide in response to these comments, w e may have additional comments.

Director Compensation, Page 43

1. Please revise the footnotes to match the data in the table. For example, you appear to be missing footnote 3 and footnote 4 addresses Mr. Stromen, rather than Mr. Cox.

2. Please clarify the director fees earned by Mr. Cox. The table discloses $20,667 but the footnote discloses $30,000.

3. Footnote 7 to the table indicates that Mr. Stromen, not Cox, received the option award but the table shows the opposite. Please reconcile this disclosure.

Exhibit 5.1

4. Please file an updated legality opinion covering all the shares you have registered.

Dennis P. Calvert BioLargo, Inc. February 8, 2018 Page 2

We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Refer to Rules 460 and 461 regarding requests for accel eration . Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement.

You may contact Kate McHale, Staff Attorney at (202) 551 -3464 or me at (202) 551 - 3397 with any other questions.

Sincerely,
/s/ Jay Ingram

Show Raw Text
February 8, 2018
Dennis P. Calvert
Chief Executive Officer,
BioLargo, Inc.
14921 Chestnut St.
Westminster, CA 92683

Re: BioLargo, Inc .
  Amendment No. 1 to Registration Statement on Form S-1
Filed  February 7 , 2018
  File No.  333-222572

Dear Mr. Calvert:

We have limited our review of your registration statement to those issues we have
addressed in our comments.  In  some of our comments, we may ask you to provide us with
information so we may better understand your disclosure.

Please respond to this letter by amending your registration statement and providing the
requested information .  If you do not believe our com ments apply to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.

After reviewing any amendment to your registration statement and the information you
provide in response to these  comments, w e may have  additional comments.

Director Compensation, Page 43

1. Please revise the footnotes to match the data in the table.  For example, you appear to be
missing footnote 3 and footnote 4 addresses Mr. Stromen, rather than Mr. Cox.

2. Please clarify the  director fees earned by Mr. Cox.  The table discloses $20,667 but the
footnote discloses $30,000.

3. Footnote 7 to the table indicates that Mr. Stromen, not Cox, received the option award but
the table shows the opposite.  Please reconcile this disclosure.

Exhibit 5.1

4. Please file an updated legality opinion covering all the shares you have registered.

Dennis P. Calvert
BioLargo, Inc.
February 8, 2018
Page 2

 We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

Refer to Rules 460 and 461 regarding requests for  accel eration .  Please allow adequate
time for us to review any amendment prior to the requested effective date of the registration
statement.

You may contact Kate McHale, Staff Attorney  at (202) 551 -3464 or me at (202) 551 -
3397  with any other questions.

Sincerely,

/s/ Jay Ingram

Jay Ingram
Legal Branch Chief
Office of Manufacturing and
Construction